Cargando…
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a...
Autores principales: | Ballotti, Robert, Cheli, Yann, Bertolotto, Corine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718690/ https://www.ncbi.nlm.nih.gov/pubmed/33276788 http://dx.doi.org/10.1186/s12943-020-01290-7 |
Ejemplares similares
-
Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma
por: Wiedemann, Gabriela M, et al.
Publicado: (2018) -
Immune Checkpoints in Cancers: From Signaling to the Clinic
por: Pisibon, Céline, et al.
Publicado: (2021) -
The “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”
por: Strub, Thomas, et al.
Publicado: (2020) -
CD271 is an imperfect marker for melanoma initiating cells
por: Cheli, Yann, et al.
Publicado: (2014) -
FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells
por: Bourseguin, Julie, et al.
Publicado: (2016)